A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

摘要

Purpose No standard of care exists for patients with metastatic pancreatic cancer following progression on first-line chemotherapy. Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population.